Seattle Genetics is a biotechnology firm that develops antibody-based therapies whose purpose is to treat cancer. It is currently the best in its industry in the production of antibody-drug conjugates commonly referred to as ADC’s. The production of ADC’s is in line with its vision which is to improve the lives of people who live with cancer through breakthrough antibody body therapies. Seattle Genetics ADC technology is meant to treat cancer without causing the many side effects that are associated with chemotherapy. The firm designed ADC to help monoclonal antibodies to deliver the agents that kill cells directly to the cancer cells while avoiding the rest of the cells. In addition to this product, the firm is also in the process of developing a product pipeline that will address other unmet medical issues.
Seattle Genetics has adamant values, chief among them being the passion for helping patients. Its other values include Integrity, teamwork and mutual respect, scientific excellence, great work environment and innovation. A solid management runs the firm under the supervision of a board of directors. The members are well versed and experienced in their respective fields and have credible papers to back up their expertise.The company operates within the rules governing business and the healthcare laws. Its aim is to build a trusting relationship with the health professionals, customers, and patients.
The company was co-founded by Dr. Clay B. Siegall in 1998 and he is the current Chairman of the Board and Chief Executive Officer. Dr. Clay is also a sits on the boards of Ultragenyx Pharmaceuticals, Mirna Therapeutics, and Alder Biopharmaceuticals. The many board memberships can be attributed to the fact that he has many years of experience in the genetics world and has a bachelor’s in zoology and a Ph. D in genetics. For his outstanding work, Dr. Clay received an award from Ernst and Young as the entrepreneur of the year in 2012.